RIPK1 targeting protects against obesity and atherosclerosis

0544814 - ÚMG 2022 RIV GB eng O - Ostatní výsledky
Sohrabi, Yahya - Reinecke, H.
RIPK1 targeting protects against obesity and atherosclerosis.
Trends in Endocrinology and Metabolism. Elsevier. Roč. 32, č. 7 (2021), s. 420-422. ISSN 1043-2760. E-ISSN 1879-3061
Institucionální podpora: RVO:68378050
Klíčová slova: RIPK1 * atherosclerosis * fatty liver * inflammation * obesity * trained immunity
Obor OECD: Endocrinology and metabolism (including diabetes, hormones)
Způsob publikování: Omezený přístup
https://www.cell.com/trends/endocrinology-metabolism/fulltext/S1043-2760(21)00070-9?_returnURL=https%3A%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS1043276021000709%3Fshowall%3Dtrue

Unhealthy lifestyles and dietary habits often lead to diet-associated inflammatory diseases such as obesity and atherosclerosis. Recent studies have provided novel insight into the role of RIPK1 in inflammation and metabolism. RIPK1 silencing can reduce diet-induced obesity, nonalcoholic fatty liver disease (NAFLD), and atherosclerosis by reducing inflammation, lipid synthesis, and inflammasome activation. Targeting RIPK1 may therefore attenuate chronic metabolic disease and would likely be therapeutic.
Trvalý link: http://hdl.handle.net/11104/0321621